Status:
COMPLETED
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Thyroid Neoplasms
Eligibility:
All Genders
20-68 years
Phase:
PHASE3
Brief Summary
This study was conducted in patients with differentiated thyroid cancer who had undergone near-total thyroidectomy. After surgery patients were randomized to one of two methods of performing thyroid r...
Detailed Description
Following a total/near-total thyroidectomy, eligible patients provided written informed consent within 14 days post-surgery. Patients were then randomized to 1 of 2 groups: the Euthyroid or the Hypoth...
Eligibility Criteria
Inclusion
- Patients who were at least 18 years old (male or female).
- Patients with newly diagnosed differentiated papillary or follicular thyroid carcinoma, including papillary-follicular variant, characterized as "T2, N0 or N1, and M0" or as "T1, N1, and M0".
- Patients with a total or near-total thyroidectomy within 2 weeks prior to enrollment.
Exclusion
- see above
Key Trial Info
Start Date :
December 1 2001
Trial Type :
INTERVENTIONAL
End Date :
September 1 2003
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00196729
Start Date
December 1 2001
End Date
September 1 2003
Last Update
March 18 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.